Ocular Toxicity of Commercially Available Belantamab Mafodotin in Patients with Advanced Multiple Myeloma

被引：1
|
作者：
Abeykoon, Jithma P. [1 ]
Vaxman, Luliana [2 ]
Patel, Sanjay V. [2 ]
Kumar, Shaji [3 ]
Young, Kimberly S. [2 ]
Ailawadhi, Sikander [4 ]
Larsen, Jeremy T. [5 ]
Gonsalves, Wilson I. [6 ]
Kourelis, Taxiarchis [1 ]
Leung, Nelson [7 ]
Warsame, Rahma M. [1 ]
Hobbs, Miriam A. [1 ]
Fonder, Amie [1 ]
Hwa, Yi L. [1 ]
Bergsage, P. Leif [8 ]
Lacy, Martha Q. [6 ]
kumar, S. Vincent Raj [1 ]
Gertz, Morie A. [1 ]
Kapoor, Prashant [1 ]
机构：
[1] Mayo Clin, Div Hematol, Rochester, MN USA
[2] Mayo Clin, Rochester, NY USA
[3] Mayo Clin, Rochester, MN USA
[4] Mayo Clin, Div Hematol, Jacksonville, FL USA
[5] Mayo Clin, Div Hematol, Phoenix, AZ USA
[6] Mayo Sch Grad Med Educ, Div Hematol, Rochester, MN USA
[7] Mayo Clin Rochester, Div Hematol, Rochester, MN USA
[8] Mayo Clin, Div Hematol, Scottsdale, AZ USA
来源：
BLOOD | 2021年 / 138卷
关键词：
D O I：
10.1182/blood-2021-154183
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：5
相关论文
共 50 条
  • [41] Effectiveness and Safety of Belantamab Mafodotin in Patients with Relapsed or Refractory Multiple Myeloma in RealLife Setting: The ALFA Study
    Roussel, Murielle
    Texier, Nathalie
    Germain, Raphael
    Sapra, Sandhya
    Paka, Prani
    Kerbouche, Naima
    Colin, Xavier
    Leleu, Xavier
    BLOOD, 2022, 140 : 4261 - 4263
  • [42] Ocular Health of Patients with Relapsed/Refractory Multiple Myeloma (RRMM): Baseline Data from the DREAMM-2 Trial of Belantamab Mafodotin (Belamaf)
    Popat, Rakesh
    Kazantzi, Aikaterini
    Farooq, Asim
    Thulasi, Praneetha
    Lonial, Sagar
    Jakubowiak, Andrzej
    Badros, Ashraf Z.
    Jeng, Bennie H.
    Opalinska, Joanna
    Baron, January
    Piontek, Trisha
    Byrne, Julie
    Womersley, Lynsey
    Gupta, Ira
    Esposti, Simona Degli
    BLOOD, 2020, 136
  • [43] Management of belantamab mafodotin-associated corneal events in patients with relapsed or refractory multiple myeloma (RRMM)
    Lonial, Sagar
    Nooka, Ajay K.
    Thulasi, Praneetha
    Badros, Ashraf Z.
    Jeng, Bennie H.
    Callander, Natalie S.
    Potter, Heather A.
    Sborov, Douglas
    Zaugg, Brian E.
    Popat, Rakesh
    Degli Esposti, Simona
    Byrne, Julie
    Opalinska, Joanna
    Baron, January
    Piontek, Trisha
    Gupta, Ira
    Dana, Reza
    Farooq, Asim V.
    Colby, Kathryn
    Jakubowiak, Andrzej
    BLOOD CANCER JOURNAL, 2021, 11 (05)
  • [44] Occurrence of corneal microcystoid alterations under administration of belantamab mafodotin for multiple myeloma
    Zimmermann, Julian
    Esser, E.
    Eter, N.
    Schuett, P.
    Uhlig, C. E.
    OPHTHALMOLOGIE, 2023, 120 (07): : 747 - 750
  • [45] Real-world outcomes of belantamab mafodotin monotherapy in triple class refractory patients with multiple myeloma
    Ntanasis-Stathopoulos, Ioannis
    Malandrakis, Panagiotis
    Fotiou, Despina
    Migkou, Magdalini
    Roussou, Maria
    Eleutherakis-Papaiakovou, Evangelos
    Theodorakakou, Foteini
    Spiliopoulou, Vassiliki
    Kastritis, Efstathios
    Terpos, Evangelos
    Dimopoulos, Meletios
    Gavriatopoulou, Maria
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S203 - S204
  • [46] Management of belantamab mafodotin-associated corneal events in patients with relapsed or refractory multiple myeloma (RRMM)
    Sagar Lonial
    Ajay K. Nooka
    Praneetha Thulasi
    Ashraf Z. Badros
    Bennie H. Jeng
    Natalie S. Callander
    Heather A. Potter
    Douglas Sborov
    Brian E. Zaugg
    Rakesh Popat
    Simona Degli Esposti
    Julie Byrne
    Joanna Opalinska
    January Baron
    Trisha Piontek
    Ira Gupta
    Reza Dana
    Asim V. Farooq
    Kathryn Colby
    Andrzej Jakubowiak
    Blood Cancer Journal, 11
  • [47] Belantamab Mafodotin in Patients with Relapsed/Refractory Multiple Myeloma, a Real-World Single Center Experience
    Hultcrantz, Malin
    Derkach, Andriy
    Hassoun, Hani
    Korde, Neha
    Maclachlan, Kylee H.
    Mailankody, Sham
    Patel, Dhwani
    Shah, Urvi A.
    Tan, Carlyn
    Akhlaghi, Theresia
    Hamadeh, Issam S.
    Chung, David J.
    Lahoud, Oscar B.
    Landau, Heather
    Scordo, Michael
    Shah, Gunjan L.
    Giralt, Sergio A.
    Lesokhin, Alexander M.
    Usmani, Saad
    BLOOD, 2022, 140 : 7246 - 7248
  • [48] Population pharmacokinetics of belantamab mafodotin, a BCMA-targeting agent in patients with relapsed/refractory multiple myeloma
    Rathi, Chetan
    Collins, Jon
    Struemper, Herbert
    Opalinska, Joanna
    Jewell, Roxanne C.
    Ferron-Brady, Geraldine
    CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY, 2021, 10 (08): : 851 - 863
  • [49] Ocular Adverse Events in Transplant Ineligible Patients with Newly Diagnosed Multiple Myeloma Treated with Belantamab Mafodotin, Lenalidomide, and Dexamethasone in a Phase 1/2 Trial
    Terpos, Evangelos
    Ntanasis-Stathopoulos, Ioannis
    Gavriatopoulou, Maria
    Malandrakis, Panagiotis
    Fotiou, Despina
    Kanellias, Nikolaos
    Migkou, Magdalini
    Theodorakakou, Foteini
    Spiliopoulou, Vasiliki
    Syrigou, Rodanthi
    Papaiakovou, Evangelos Eleutherakis
    Gkolfinopoulos, Stavros
    Manousou, Kyriaki
    Kastritis, Efstathios
    Dimopoulos, Meletios A.
    BLOOD, 2022, 140 : 7267 - 7268
  • [50] Ocular adverse events and functional impact in transplant ineligible, newly diagnosed multiple myeloma patients treated with belantamab mafodotin, lenalidomide and dexamethasone in BelaRd trial
    Terpos, Evangelos
    Ntanasis-Stathopoulos, Ioannis
    Gavriatopoulou, Maria
    Malandrakis, Panagiotis
    Fotiou, Despina
    Migkou, Magdalini
    Theodorakakou, Foteini
    Spiliopoulou, Vassiliki
    Syrigou, Rodanthi
    Eleutherakis-Papaiakovou, Evangelos
    Gkolfinopoulos, Stavros
    Manousou, Kyriaki
    Kastritis, Efstathios
    Dimopoulos, Meletios
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S102 - S103
12345